Advertisement

Molecular Biology Reports

, Volume 38, Issue 7, pp 4491–4494 | Cite as

Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility

  • Li-Xin Qiu
  • Ke Wang
  • Sheng Yang
  • Chen Mao
  • Lei Zhao
  • Lei Yao
  • Jian Zhang
  • Qun-Ling Zhang
  • Si Sun
  • Kai Xue
Article

Abstract

Several polymorphisms of vascular endothelial growth factor (VEGF) such as 936 C/T, −2578 C/A, −406 C/T, and −1154 G/A polymorphism have been identified. Published data on the association between VEGF polymorphisms and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude OR with 95% CI was used to assess the strength of association between them. For VEGF 936C/T polymorphism, a total of 10 studies including 7,685 cases and 7,915 controls were involved in this meta-analysis. Overall, no significant associations were found between VEGF 936C/T polymorphism and breast cancer risk when all studies pooled into the meta-analysis (TC vs. CC: OR = 0.904, 95% CI = 0.797–1.024; TT vs. CC: OR = 0.974, 95% CI = 0.786–1.205; dominant model: OR = 0.911, 95% CI = 0.811–1.024; and recessive model: OR = 0.991, 95% CI = 0.801–1.226). In the subgroup analysis by ethnicity, still no significant associations were found for all comparison models. For −2578 C/A, −406 C/T, and −1154 G/A polymorphism, there were too limited data to perform a meta-analysis. In conclusion, this meta-analysis suggests that the VEGF 936C/T polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted to confirm this finding.

Keywords

VEGF Polymorphism Breast cancer Susceptibility 

Notes

Conflict of interest statement

All authors declared no potential conflicts of interest.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85PubMedCrossRefGoogle Scholar
  3. 3.
    Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803PubMedCrossRefGoogle Scholar
  4. 4.
    Chae YS, Kim JG, Sohn SK (2006) Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 71:e72–e78CrossRefGoogle Scholar
  5. 5.
    Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48:e9–e15CrossRefGoogle Scholar
  6. 6.
    Renner W, Kotschan S, Hoffmann C (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448PubMedCrossRefGoogle Scholar
  7. 7.
    Jakubowska A, Jaworska K, Cybulski C (2009) Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer 45:837–842PubMedCrossRefGoogle Scholar
  8. 8.
    Lin GT, Tseng HF, Yang CH (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 13:165–173PubMedCrossRefGoogle Scholar
  9. 9.
    Balasubramanian SP, Cox A, Cross SS (2007) Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 121:1009–1016PubMedCrossRefGoogle Scholar
  10. 10.
    Kataoka N, Cai Q, Wen W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15:1148–1152PubMedCrossRefGoogle Scholar
  11. 11.
    Jacobs EJ, Feigelson HS, Bain EB (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the cancer prevention study II cohort. Breast Cancer Res 8:R22–R27PubMedCrossRefGoogle Scholar
  12. 12.
    Jin Q, Hemminki K, Enquist K (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653PubMedCrossRefGoogle Scholar
  13. 13.
    Krippl P, Langsenlehner U, Renner W (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471PubMedCrossRefGoogle Scholar
  14. 14.
    Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BAJ (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42–e47PubMedCrossRefGoogle Scholar
  15. 15.
    Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  16. 16.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  17. 17.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  18. 18.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  19. 19.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  20. 20.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:e57–e63CrossRefGoogle Scholar
  21. 21.
    Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRefGoogle Scholar
  22. 22.
    Hirschhorn JN, Lohmueller K, Byrne E (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61PubMedCrossRefGoogle Scholar
  23. 23.
    Qiu LX, Zhang J, Zhu XD, Zheng CL, Sun S, Wang ZH (2010) The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51, 236 subjects. Breast Cancer Res Treat 124:475–479PubMedCrossRefGoogle Scholar
  24. 24.
    Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K (2010) XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28, 709 subjects. Breast Cancer Res Treat 124:229–235PubMedCrossRefGoogle Scholar
  25. 25.
    Qiu LX, Yao L, Mao C, Chen B, Zhan P, Xue K (2010) TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47, 817 subjects. Breast Cancer Res Treat 123:563–567PubMedCrossRefGoogle Scholar
  26. 26.
    Qiu LX, Yao L, Xue K, Zhang J, Mao C, Chen B (2010) BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44, 903 subjects. Breast Cancer Res Treat 123:487–490PubMedCrossRefGoogle Scholar
  27. 27.
    Qiu LX, Yuan H, Yu KD (2010) Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46, 281 subjects. Breast Cancer Res Treat 121:703–708PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Li-Xin Qiu
    • 1
    • 2
  • Ke Wang
    • 3
  • Sheng Yang
    • 4
  • Chen Mao
    • 5
  • Lei Zhao
    • 6
  • Lei Yao
    • 7
  • Jian Zhang
    • 1
    • 2
  • Qun-Ling Zhang
    • 1
    • 2
  • Si Sun
    • 1
    • 2
  • Kai Xue
    • 1
    • 2
  1. 1.Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of OncologyShanghai Medical College, Fudan UniversityShanghaiChina
  3. 3.Institute of Respiratory DiseasesFirst Affiliated Hospital, Guangxi Medical UniversityNanningChina
  4. 4.Department of Medical OncologyUnion Hospital, Fu Jian Medical UniversityFuzhouChina
  5. 5.Department of EpidemiologySchool of Public Health and Tropical Medicine, Southern Medical UniversityGuangzhouChina
  6. 6.Department of Epidemiology, School of Public HealthWuhan UniversityWuhanChina
  7. 7.State Key Laboratory of Genetic EngineeringInstitute of Genetics, School of Life Sciences, Fudan UniversityShanghaiChina

Personalised recommendations